Head to Head Contrast: Arcturus Therapeutics (NASDAQ:ARCT) versus Candel Therapeutics (NASDAQ:CADL)

Candel Therapeutics (NASDAQ:CADL) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Candel Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1	2	8	0	2.64
Arcturus Therapeutics	1	3	5	1	2.60

Candel Therapeutics presently has a consensus price target of $19.29, indicating a potential upside of 47.56%. Arcturus Therapeutics has a consensus price target of $20.00, indicating a potential upside of 31.67%. Given Candel Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Candel Therapeutics is more favorable than Arcturus Therapeutics.

Volatility and Risk

Candel Therapeutics has a beta of -0.51, suggesting that its share price is 151% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500.

Earnings and Valuation

This table compares Candel Therapeutics and Arcturus Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18 million	($1.41)	-9.27
Arcturus Therapeutics	$82.03 million	5.26	-$65.78 million	($3.31)	-4.59

Candel Therapeutics has higher earnings, but lower revenue than Arcturus Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Candel Therapeutics and Arcturus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Summary

Arcturus Therapeutics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.